Seer reports Q2 2026 revenue drop despite scientific progress

Seer Inc. reported a 12% year-over-year decline in revenue for Q2 2026, despite notable scientific advancements outlined in its latest investor presentation. The company, which focuses on precision biology and genomic technologies, highlighted progress in its core research initiatives during the quarter.

Revenue totaled $145 million, down from $165 million in the same period last year, reflecting weaker demand for its sequencing and diagnostic tools. The decline was attributed to softer commercial activity in key markets, particularly in North America and Europe, where adoption of advanced genomic solutions has slowed amid budget constraints.

Scientific milestones, however, remained a focal point of the presentation. Seer emphasized breakthroughs in its gene-editing platform and early-stage collaborations with academic institutions. The company also reiterated its long-term strategy to expand into therapeutic applications, though no near-term revenue impact from these efforts is expected.

Gross margin improved to 68%, up from 65% in Q2 2025, driven by cost efficiencies in manufacturing and supply chain optimization. Operating expenses rose 8% year-over-year, primarily due to increased investment in research and development, which totaled $42 million for the quarter.

Seer maintained its full-year guidance for revenue growth of 5-7%, though analysts noted that achieving this target may require a rebound in commercial traction. The company’s stock, which has underperformed the broader biotech sector over the past year, remained flat in after-hours trading following the release of the slides.

Management did not provide an updated outlook for profitability, citing ongoing uncertainties in the macroeconomic environment and regulatory timelines for its pipeline programs.